Brokers Offer Predictions for ETRA Q3 Earnings

Electra Therapeutics, Inc. (NASDAQ:ETRA) – Stock analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of Electra Therapeutics in a research report issued to clients and investors on Monday, October 26th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.56) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Electra Therapeutics’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for Electra Therapeutics’ Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($3.17) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.64) EPS, Q4 2027 earnings at ($0.70) EPS and FY2027 earnings at ($2.48) EPS.

ETRA has been the topic of a number of other research reports. Evercore began coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set an “outperform” rating and a $36.00 price objective on the stock. Jefferies Financial Group started coverage on Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating and a $32.00 target price for the company. TD Cowen began coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They set a “buy” rating for the company. Wall Street Zen raised shares of Electra Therapeutics to a “hold” rating in a research note on Saturday, September 26th. Finally, Cantor Fitzgerald initiated coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Electra Therapeutics has an average rating of “Buy” and an average price target of $33.50.

Electra Therapeutics Stock Up 1.8%

ETRA opened at $8.52 on Wednesday. Electra Therapeutics has a 1-year low of $8.26 and a 1-year high of $15.50.

Insider Buying and Selling at Electra Therapeutics

In other Electra Therapeutics news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the stock in a transaction dated Monday, September 21st. The stock was acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares in the company, valued at $76,903,365. This trade represents a 35.15% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Carl Gordon acquired 1,333,333 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the completion of the transaction, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. The SEC filing for this purchase provides additional information.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.

Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.